Neurological Complications of Transplantation: Part I: Hematopoietic Cell Transplantation

The Neurohospitalist

Volumn 3, Issue 1, 2013, Pages 24-38

  Pruitt, Amy A ^a   Rosenfeld, Myrna R ^a   Graus, Francesc ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Aspergillus; graft versus host disease; hematopoietic cell transplantation; immune reconstitution inflammatory syndrome; organ transplantation; posterior reversible encephalopathy syndrome; posttransplantation lymphoproliferative disorder; progressive multifocal leukoencephalopathy; varicella zoster virus

Indexed keywords

EID: 84992791405     PISSN: 19418744     EISSN: 19418752     Source Type: Journal    
DOI: 10.1177/1941874412455338     Document Type: Review

References (111)

1. Quant E, Wen PY. Neurological complications of hematopoietic stem cell transplantation. Cancer Neurology in Clinical Practice, Neurologic Complications of Cancer and Its Treatment, Second Edition. In: SchiffD, Kesari S,WenPY, eds. Totawa, NJ: Humana Press; 2008: 327–351.
2. Hart DP, Peggs KS. Current status of allogeneic stem cell transplantation for treatment of hematologic malignancies. Clin Pharmacol Ther. 2007; 82(3):325–329.
3. Strober J, Cowan MJ, Horn BN. Allogeneic hematopoietic cell transplantation for refractory myasthenia gravis. Arch Neurol. 2009; 66(5):659–661.
4. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006; 354(7):1813–1826.
5. Gratwohl A, Passweg J, Baldomero H, Horisberger B, Urbano-Ispizua A. Economics, health care systems and utilization of haematopoietic stem cell transplants in Europe. Br J Haematol. 2002; 117(2):451–468.
6. Center for International Blood and Marrow Transplant Research. Progress Report: January-December 2007. Milwaukee, WI: CIBMTR; 2008.
7. Straathof KC, Rao K, Eyrich M, et alHaemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study. Lancet. 2009; 374(9693):912–920.
8. Tomblyn M, Chiller T, Einsele H, et alGuidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009; 15(10):1143–1238.
9. Denier C, Bourhis JH, Lacroix C, et alSpectrum and prognosis of neurologic complications after hematopoietic transplantation. Neurology. 2006; 67(11):1990–1997.
10. Sostak P, Padovan CS, Yousry TA, Ledderose G, Kolb HJ, Straube A. Prospective evaluation of neurological complications after allogeneic bone marrow transplantation. Neurology. 2003; 60(5):842–848.
11. Siegal D, Keller A, Xu W, et alCentral nervous system complications after allogeneic hematopoietic stem cell transplantation: incidence, manifestations, and clinical significance. Biol Blood Marrow Transplant. 2007; 13(11):1369–1379.
12. Uckan D, Cetin M, Yigitkanli I, et alLife-threatening neurological complications after bone marrow transplantation in children. Bone Marrow Transplant. 2005; 35(1):71–76.
13. Barba P, Pinana JL, Valcarcel D, et alEarly and late neurological complications after reduced-intensity conditioning allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2009; 15(11):1439–1446.
14. Weber C, Schaper J, Tibussek D, et alDiagnostic and therapeutic implications of neurological complications following paediatric haematopoietic stem cell transplantation. Bone Marrow Transplant. 2008; 41(3):253–259.
15. Craddock CF. Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML. Bone Marrow Transplant. 2008; 41(5):415–423.
16. Saiz A, Graus F. Neurological complications of hematopoietic cell transplantation. Semin Neurol. 2004; 24(4):427–434.
17. Bleggi-Torres LF, de Medeiros BC, Werner B, et alNeuropathological findings after bone marrow transplantation: an autopsy study of 180 cases. Bone Marrow Transplant. 2000; 25(3):301–307.
18. Rosenfeld MR, Pruitt A. Neurologic complications of bone marrow, stem cell, and organ transplantation in patients with cancer. Semin Oncol. 2006; 33(3):352–361.
19. Grauber JJ, Nolan CP. Myelopathes in patients with cancer. Arch Neurol. 2010; 67(3):298–304.
20. Jagannathan JP, Ramaiya N, Gill RR, Alyea EP III, Ros P. Imaging of complications of hematopoietic stem cell transplantation. Radiol Clin North Am. 2008; 46(2):397–417.
21. Carrera E, Claassen J, Oddo M, Emerson RG, Mayer SA, Hirsch LJ. Continuous electroencephalographic monitoring in critically ill patients with central nervous system infections. Arch Neurol. 2008; 65(12):1612–1618.
22. Weathers AL, Lewis SL. Rare and unusual or are they? Less commonly diagnosed encephalopathies associated with systemic disease. Semin Neurol. 2009; 29(2):136–153.
23. Burt RK, Fassas A, Snowden J, et alCollection of hematopoietic stem cells from patients with autoimmune diseases. Bone Marrow Transplant. 2001; 28(1):1–12.
24. Openshaw H, Stuve O, Antel JP, et alMultiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor. Neurology. 2000; 54(11):2147–2150.
25. Chen-Plotkin AS, Vossel KA, Samuels MA, Chen MH. Encephalopathy, stroke, and myocardial infarction with DMSO use in stem cell transplantation. Neurology. 2007; 68(11):859–861.
26. Otrock ZK, Beydoun A, Barada WM, Masroujeh R, Hourani R, Bazarbachi A. Transient global amnesia associated with the infusion of DMSO-cryopreserved autologous peripheral blood stem cells. Haematologica. 2008; 93(3): e36–e37.
27. Ajithkumar T, Parkinson C, Shamshad F, Murray P. Ifosfamide encephalopathy. Clin Oncol (R Coll Radiol). 2007; 19(2):108–114.
28. Sweiss KI, Beri R, Shord SS. Encephalopathy after high-dose Ifosfamide: a retrospective cohort study and review of the literature. Drug Saf. 2008; 31(11):989–996.
29. Howell JE, Szabatura AH, Hatfield SA, Nesbit SA. Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant. J Oncol Pharm Pract. 2008; 14(3):157–162.
30. Somech R, Doyle J. Pseudotumor cerebri after allogeneic bone marrow transplant associated with cyclosporine a use for graft-versus-host disease prophylaxis. J Pediatr Hematol Oncol. 2007; 29(1):66–68.
31. Sierra-Hidalgo F, Martinez-Salio A, Moreno-Garcia S, Pablo-Fernandez E, Correas-Callero E, Ruiz-Morales J. Akinetic mutism induced by tacrolimus. Clin Neuropharmacol. 2009; 32(5):293–294.
32. Lake DB, Poole TR. Tacrolimus. Br J Ophthalmol. 2003; 87(1):121–122.
33. Balu R, Pruitt AA. Neurologic complications of immunosuppressive drugs. In: WenPY,SchiffD,Quant LeeE, eds. Neurologic Complications of Cancer Therapy. New York, NY: Demos Medical; 2012: 107–124.
34. Al Masri O, Fathallah W, Quader S. Recovery of tacrolimus-associated brachial neuritis after conversion to everolimus in a pediatric renal transplant recipient—case report and review of the literatuure. Pediatr Transplant. 2008; 12(8):914–917.
35. Kim SH, Kin W, Lee KW, Hong EK, Kim HJ. Tumefactive demyelination as an uncommon form of tacrolimus neurotoxicity. Neurology. 2011; 76(7):672–674.
36. Gocmen R, Ozgen B, Oguz KK. Widening the spectrum of PRES: series from a tertiary care center. Eur J Radiol. 2007; 62(3):454–459.
37. Bhatt A, Farooq MU, Majid A, Kassab M. Chemotherapy-related posterior reversible leukoencephalopathy syndrome. Nat Clin Pract Neurol. 2009; 5(3):163–169.
38. Nguyen MT, Virk IY, Chew L, Villano JL. Extended use dexamethasone-associated posterior reversible encephalopathy syndrome with cisplatin-based chemotherapy. J Clin Neurosci. 2009; 16(12):1688–1690.
39. Hefzy HM, Bartynski WS, Boardman JF, Lacomis D. Hemorrhage in posterior reversible encephalopathy syndrome: imaging and clinical features. AJNR Am J Neuroradiol. 2009; 30(7):1371–1379.
40. McKinney AM, Short J, Truwit CL, et alPosterior reversible encephalopathy syndrome: incidence of atypical regions of involvement and imaging findings. AJR Am J Roentgenol. 2007; 189(4):904–912.
41. Briganti C, Caulo M, Notturno F, Tartaro A, Uncini A. Asymptomatic spinal cord involvement in posterior reversible encephalopathy syndrome. Neurology. 2009; 73(18):1507–1508.
42. Kozak OS, Wijdicks EF, Manno EM, Miley JT, Rabinstein AA. Status epilepticus as initial manifestation of posterior reversible encephalopathy syndrome. Neurology. 2007; 69(9):894–897.
43. Feske SK. Posterior reversible encephalopathy syndrome: a review. Semin Neurol. 2011; 31(2):202–215.
44. Fugate JE, Claassen DO, Cloft HJ, Kallmes DF, Kozak OS, Rabinstein AA. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findigs. Mayo Clin Proc. 2010; 85(5):427–432.
45. Skiba V, Etienne M, Miller JA. Development of chronic epilepsy after recurrent episodes of posterior reversible encephalopathy syndrome associated with periodic lateralized epileptiform discharges. Seizure. 2011; 20(1):93–95.
46. Batts ED, Lazarus HM. Diagnosis and treatment of transplantation-associated thrombotic microangiopathy: real progress or are we still waiting? Bone Marrow Transplant. 2007; 40(8):709–719.
47. McDonald GB. Hepatobiliary complications of hematopoietic cell transplantation, 40 years on. Hepatology. 2010; 51(4):1450–1460.
48. Safdar A, Papadopoulous EB, Armstrong D. Listeriosis in recipients of allogeneic blood and marrow transplantation: thirteen year review of disease characteristics, treatment outcomes and a new association with human cytomegalovirus infection. Bone Marrow Transplant. 2002; 29(11):913–916.
49. Wiesmayr S, Tabarelli W, Stelzmueller I, et alListeria meningitis in transplant recipients. Wien Klin Wochenschr. 2005; 117(5-6):229–233.
50. Teive HA, Funke V, Bitencourt MA, et alNeurological complications of hematopoietic stem cell transplantation (HSCT): a retrospective study in a HSCT center in Brazil. Arq Neuropsiquiatr 2008; 66(3B):685–690.
51. Krouwer HG, Wijdicks EF. Neurologic complications of bone marrow transplantation. Neurol Clin. 2003; 21(1):319–352.
52. Cree BC, Bernardini GL, Hays AP, Lowe G. A fatal case of coxsackievirus B4 meningoencephalitis. Arch Neurol. 2003; 60(1):107–112.
53. Shaz BH. Transfusion transmitted diseases. In: HilyerCD,ShazBH,ZimringJG,AbshireTC, eds. Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects. New York, NY: Elsevier, 2009: 361–371.
54. Iwamoto M, Jernigan DB, Guasch A, et alTransmission of West Nile virus from an organ donor to four transplant recipients. N Engl J Med. 2003; 348(22):2196–2203.
55. Fischer SA, Graham MB, Kuehnert MJ, et alTransmission of lymphocytic choriomeningitis virus by organ transplantation. N Engl J Med. 2006; 354(21):2235–2249.
56. Burton EC, Burns DK, Opatowsky MJ, et alRabies encephalomyelitis: clinical, neuroradiological, and pathological findings in 4 transplant recipients. Arch Neurol. 2005; 62(6):873–882.
57. Seeley WW, Marty FM, Holmes TM, et alPost-transplant acute limbic encephalitis: clinical features and relationship to HHV6. Neurology. 2007; 69(2):156–165.
58. Seishima M, Yamanaka S, Fijisawa T, Tohyama M, Hashimoto K. Reactivation of human herpesvirus (HHV) family members other than HHV-6 in drug-induced hypersensitivity syndrome. Br J Dermatol. 2006; 155(2):344–349.
59. Natkunarajah J, Watson K, Diaz-Cano S, Mufti G, du Vivier A, Creamer D. Drug rash with eosinophilia and systemic symptoms and graft-versus-host disease developing sequentially in a patient. Clin Exp Dermatol. 2009; 34(2):199–201.
60. Airas L, Paivarinta M, Roytta M, et alCentral nervous system immune reconstitution inflammatory syndrome (IRIS) after hematopoietic SCT. Bone Marrow Transplant. 2010; 45(3):593–596.
61. Thachil J, Jadhav V, Gautam M, et alThe development of sarcoidosis with the use of alemtuzumab- clues to T-cell immune reconstitution. Br J Haematol. 2007; 138(4):559–560.
62. Ingram PR, Howman R, Leahy MF, Dyer JR. Cryptococcal immune reconstitution inflammatory syndrome following alemtuzumab therapy. Clin Infect Dis. 2007; 44(12): e115–e117.
63. Cesaro S, Boaro MP, Pillon M, et alImmune reconstitution complicated by CMV retinitis in a pediatric patient who underwent haploidentical CD34+-selected hematopoietic stem cell transplant for acute lymphoblastic leukemia. Int J Hematol. 2008; 88(2):145–148.
64. Perfect JR. The impact of the host on fungal infections Am J Med. 2012; 125(1 suppl): S39–S51.
65. Ruping MJ, Vehreschild JJ, Cornely OA. Patients at high risk of invasive fungal infections: when and how to treat. Drugs. 2008; 68(14):1941–1962.
66. Thursky KA, Worth LJ, Seymour JF, Miles PH, Slavin MA. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab. Br J Haematol. 2006; 132(1):3–12.
67. Labbe AC, Su SH, Laverdiere M, et alHigh incidence of invasive aspergillosis associated with intestinal graft-versus-host disease following nonmyeloablative transplantation. Biol Blood Marrow Transplant. 2007; 13(10):1192–1200.
68. Narreddy S, Mellon-Reppen S, Abidi MH, et alNon-bacterial infections in allogeneic non-myeloablative stem cell transplant recipients. Transpl Infect Dis. 2007; 9(1):3–10.
69. Guermazi A, Gluckman E, Tabti B, Miaux Y. Invasive central nervous system aspergillosis in bone marrow transplantation recipients: an overview. Eur Radiol. 2003; 13(2):377–388.
70. Maertens J, Theunissen K, Verhoef G, et alGalactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis. 2005; 41(9):1242–1250.
71. Seton M, Pless M, Fishman JA, Caruso PA, Hedley-Whyte ET. Case records of the Massachusetts General Hospital. Case 18-2008. A 68-year-old man with headache and visual changes after liver transplantation. N Engl J Med. 2008; 358(24):2619–2628.
72. Kotton CN. Zoonoses in solid-organ and hematopoietic stem cell transplant recipients. Clin Infect Dis. 2007; 44(6):857–866.
73. Fricker-Hidalgo H, Bulabois CE, Brenier-Pinchart MP, et alDiagnosis of toxoplasmosis after allogeneic stem cell transplantation: results of DNA detection and serological techniques. Clin Infect Dis. 2009; 48(2): e9–e15.
74. Quan D, Hammack BN, Kittelson J, Gilden DH. Improvement of postherpetic neuralgia after treatment with intravenous acyclovir followed by oral valacyclovir. Arch Neurol. 2006; 63(7):940–942.
75. Nagel MA, Gilden DH. The protean neurologic manifestations of varicella-zoster virus infection. Cleve Clin J Med. 2007; 74(7):489–494.
76. Nakamoto BK, Dorotheo EU, Biousse V, Tang RA, Schiffman JS, Newman NJ. Progressive outer retinal necrosis presenting with isolated optic neuropathy. Neurology. 2004; 63(12):2423–2425.
77. Gilden D, Cohrs RJ, Mahalingam R, Nagel MA. Varicella zoster virus vasculopathies: diverse clinical manifestations, laboratory features, pathogenesis, and treatment. Lancet Neurol. 2009; 8(8):731–740.
78. Carson KR, Focosi D, Major EO, et alMonoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol. 2009; 10(8):816–824.
79. Kharfan-Dabaja MA, Ayala E, Greene J, Rojiani A, Murtagh FR, Anasetti C. Two cases of progressive multifocal leukoencephalopathy after allogeneic hematopoietic cell transplantation and a review of the literature. Bone Marrow Transplant. 2007; 39(2):101–107.
80. Gheuens S, Pierone G, Peeters P, Koralnik IJ. Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression. J Neurol Neurosurg Psychiatry. Published online October 14, 2009.
81. Carson KR, Evens AM, Richey EA, et alProgressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009; 113(20):4834–4840.
82. Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogénesis. Lancet Neurol. 2010; 9(4):425–437.
83. Tan K, Roda R, Ostrow L, McArthur J, Nath A. PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology. 2009; 72(17):1458–1464.
84. Cinque P, Scarpellini P, Vago L, Linde A, Lazzarin A. Diagnosis of central nervous system complications in HIV-infected patients: cerebrospinal fluid analysis by the polymerase chain reaction. AIDS. 1997; 11(1):1–17.
85. Sheikh SI, Stemmer-Rachamimov A, Attar EC. Autopsy diagnosis of progressive multifocal leukoencephalopathy with JC virus-negative CSF after cord blood stem-cell transplantation. J Clin Oncol. 2009; 27(23): e46–e47.
86. Calabrese L. A rational approach to PML for the clinician. Cleveland Clin J Med. 2011; 78(suppl 2): S38–S41.
87. Aksamit AJ. Progressive multifocal leukoencephalopathy. Curr Treat Options Neurol. 2008; 10(3):178–185.
88. Brickelmaier M, Lugovskoy A, Kartikeyan R, et alIdentification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemother. 2009; 53(5):1840–1849.
89. Elphick GF, Querbes W, Jordan JA, et alThe human polyomavirus, JCV, uses serotonin receptors to infect cells. Science. 2004; 306(5700):1380–1383.
90. Avivi I, Chakrabarti S, Kottaridis P, et alNeurological complications following alemtuzumab-based reduced-intensity allogeneic transplantation. Bone Marrow Transplant. 2004; 34(2):137–142.
91. Narimatsu H, Miyamura K, Iida H, Hamaguchi M, Uchida T, Morishita Y. Early central nervous complications after umbilical cord blood transplantation for adults. Biol Blood Marrow Transplant. 2009; 15(1):92–100.
92. Thachil J, Jadhav V, Gautam M, et alThe development of sarcoidosis with the use of alemtuzumab - clues to T-cell immune reconstitution. Br J Haematol. 2007; 138(4):559–560.
93. Tabbara KF, Al Ghamdi A, Al Mohareb F, et alOcular findings after allogeneic hematopoietic stem cell transplantation. Ophthalmology. 2009; 116(9):1624–1629.
94. Tse S, Saunders EF, Silverman E, Vajsar J, Becker L, Meaney B. Myasthenia gravis and polymyositis as manifestations of chronic graft-versus-host-disease. Bone Marrow Transplant. 1999; 23(4):397–399.
95. Kamble RT, Chang CC, Sanchez S, Carrum G. Central nervous system graft-versus-host disease: report of two cases and literature review. Bone Marrow Transplant. 2007; 39(1):49–52.
96. Grauer O, Wolff D, Bertz H, et alNeurological manifestations of chronic graft versus host disease after allogeneic stem cell transplantation: report from the Consensus Conference on Clinical Practice in chronic graft-versus-host disease. Brain. 2010; 133(10):2852–2865.
97. Campbell JN, Morris PP. Cerebral vasculitis in graft-versus-host disease: a case report. AJNR Am J Neuroradiol. 2005; 26(3):654–656.
98. Padovan CS, Bise K, Hahn J, et alAngiitis of the central nervous system after allogeneic bone marrow transplantation? Stroke. 1999; 30(8):1651–1656.
99. Ma M, Barnes G, Pulliam J, Jezek D, Baumann RJ, Berger JR. CNS angiitis in graft vs host disease. Neurology. 2002; 59(12):1994–1997.
100. Kew AK, Macaulay R, Burrell S, Rubin S, Dow G, Couban S. Central nervous system graft-versus-host disease presenting with granulomatous encephalitis. Bone Marrow Transplant. 2007; 40(2):183–184.
101. Tsutsumi Y, Kanamori H, Kawamura T, et alInflammatory pseudotumor of the brain following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2005; 35(11):1123–1124.
102. Sakai M, Ohashi K, Ohta K, et alImmune-mediated myelopathy following allogeneic stem cell transplantation. Int J Hematol. 2006; 84(3):272–275.
103. Tomonari A, Tojo A, Adachi D, et alAcute disseminated encephalomyelitis (ADEM) after allogeneic bone marrow transplantation for acute myeloid leukemia. Ann Hematol. 2003; 82(1):37–40.
104. Shortt J, Hutton E, Faragher M, Spencer A. Central nervous system graft-versus-host disease post allogeneic stem cell transplant. Br J Haematol. 2006; 132(2):245–247.
105. Matsuo Y, Kamezaki K, Takeishi S, et al. Encephalomyelitis mimicking mulitple sclerosis associated with chronic graft-versus-host disease after allogeneic bone marrow transplantation. Intern Med. 2009; 48(16):1453–1456.
106. Armstrong RJE, Elston JS, Hatton CS, Ebers GC. De Novo relapsing-remitting multiple sclerosis following autologous stem cell transplantation. Neurology. 2010; 75(1):89–91.
107. Kyllerman M, Himmelmann K, Fasth A, Nordborg C, Mansson JE. Late cerebral graft versus host reaction in a bone marrow transplanted girl with Hurler (MPS I) disease. Neuropediatrics. 2008; 39(5):249–251.
108. Sherer Y, Shoenfeld Y. Autoimmune diseases and autoimmunity post-bone marrow transplantation. Bone Marrow Transplant. 1998; 22(9):873–881.
109. Faraci M, Bekassy AN, DeFazio V, Tichelli A, Dini G. Non-endocrine late complications in children after allogeneic haematopoietic SCT. Bone Marrow Transplant. 2008; 41(suppl 2): S49–S57.
110. Diller L. Adult primary care after childhood acute lymphoblastic leukemia. N Eng J Med. 2011; 365(15):1417–1424.
111. Wong FL, Bosworth A, Danao R, et alNeurocognitive function and its impact on return to work in patients treated with hematopoietic cell transplantation (HCT). Blood. 2009; 114: 521 (abstract).